Abstract:
Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.
Abstract:
The present disclosure provides methods for enabling an individual having a cat allergy to have a cat as a pet. Such a method can include quantitatively determining a threshold in the individual for an environmental level of an allergen produced by the cat and selecting a cat or a breed of cat that creates an environmental level of the allergen that is less than the threshold. Additionally, such a method can include lowering the allergens disseminated by the cat by treating the environment inhabited by the cat during a time period where the cat expresses elevated allergens.
Abstract:
Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.
Abstract:
The invention provides methods and devices for evaluating and tracking canine physical activity by determining for a canine (1) the duration of an activity or exercise; the speed of the activity or exercise based on the type of activity or exercise pace, e.g., walking, trotting, cantering, or running; a breed category factor to accommodate speed differences in distance travelled because of differences in body size and stride length; and an age factor and (2) calculating physical activity points (PAP) for the canine using an equation designed to accept input for the variables in (1) and use those variables to calculate PAP. The results from the equation are used to evaluate the physical activity of the canine and, based upon the evaluation, alter, if required, the canine's physical activity in a way that benefits the canine, particularly the canine's health.
Abstract:
Compositions and methods reduce symptoms of human allergy to cats. The effectiveness of a molecule which specifically binds to Feline domesticus allergen number 1 (Fel D1) is enhanced by prolonging the time the immunoglobulin stays within the mouth of a cat to whom the anti-Fel D1 molecule is administered in a pet food. The compositions and methods use a powder that is a dried hydrogel encapsulating the anti-Fel D1 molecule, and the hydrogel is based on gelatin, collagen peptides, or gelatin and collagen peptides; and carrageenan. The methods of making the powder provide a high encapsulation efficacy, sustained release of the anti-Fel D1 molecule in the cat's mouth, and oral adhesion of the anti-Fel D1 molecule in the cat's mouth.
Abstract:
The present disclosure provides methods for enabling an individual having a cat allergy to have a cat as a pet. Such a method can include quantitatively determining a threshold in the individual for an environmental level of an allergen produced by the cat and selecting a cat or a breed of cat that creates an environmental level of the allergen that is less than the threshold. Additionally, such a method can include lowering the allergens disseminated by the cat by treating the environment inhabited by the cat during a time period where the cat expresses elevated allergens.
Abstract:
Formulations, compositions and products for reducing allergenic Fel d 1 from the environment are disclosed. The formulations include at least one protease that interacts with the Fel d 1 and substantially degrades allergenic epitopes on the Fel d 1. Methods of using the formulations for reducing or eliminating allergenic Fel d 1 from the environment are also disclosed.
Abstract translation:公开了用于降低环境中致敏性Fel d 1的制剂,组合物和产品。 该制剂包括与Fel d 1相互作用的至少一种蛋白酶,并且在Fel d 1上基本上降解过敏表位。还公开了使用该制剂减少或消除来自环境的过敏性Fel d 1的方法。